Frequency of Persistent Obesity 5 years After First Time Diagnosis of Status Asthmaticus

2021 ◽  
Author(s):  
Conrad Krawiec ◽  
Xinying Fang ◽  
Shouhao Zhou ◽  
Duane Williams ◽  
Neal J. Thomas
Keyword(s):  
Status Asthmaticus ◽  
First Time ◽  
Time Diagnosis

Time trends in use of cardioprotective medication in patients with peripheral artery disease between 1997 and 2016: a nationwide study

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
S Kamil ◽  
T.S.G Sehested ◽  
K Houlind ◽  
J.F Lassen ◽  
G Gislason ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Ace Inhibitors ◽  
Lifestyle Modification ◽  
Temporal Trends ◽  
Peripheral Artery ◽  
Nationwide Study ◽  
History Of ◽  
Artery Disease ◽  
First Time ◽  
Time Diagnosis

Abstract Background Peripheral artery disease (PAD) is associated with increased cardiovascular (CV) morbidity and mortality. Aggressive management of risk factors and lifestyle modification may improve outcomes for patients with PAD. The present study aims to investigate changes in use of cardioprotective medication after the incident diagnosis of PAD between 1997 and 2016. Methods By using Danish national healthcare registries, we identified all patients with first-time diagnosis of PAD between 1997 and 2016. These patients were classified into 2 main groups: PAD-all (n=167,762) that includes all PAD patients with or without a history of CVD, including myocardial infarction (MI), atrial fibrillation (AF), and stroke (n=167,761) and PAD-only (n=87,935) that comprise patients with PAD without a history of AF, MI, and stroke. We calculated temporal trends and assessed comparative use of cardioprotective medication in the first 12 months after the incident diagnosis of PAD. Results Our results showed an improved use of cardioprotective medication temporally in both groups. However, PAD-all were marginally better treated (Aspirin, 3.5% - 48.4%; Clopidogrel, 0% - 17.6%; VKA 0.9% - 7.8%; NOACs 0.0% - 10.1%; Statins, 1.9%- 58.1%; ACE-inhibitors, 1.2% - 20.6%), compared to PAD-only (Aspirin, 2.9% - 54.4%; Clopidogrel, 0% - 11.9%; VKA 0.9% - 2.4%; NOACs 0.0% - 3.4%; Statins, 1.5%- 56.9%; ACE-inhibitors, 0.9% - 17.2%), respectively. Proportion of PAD patients treated with any cardioprotective medication was greater among those with a history of MI or stroke. Whereas, PAD patients with a history of AF were substantially better treated with VKA and NOACs. Conclusion In this nationwide study, use of cardioprotective medication increased considerably with time, but there remains an underuse of guideline-recommended therapy in patients with PAD. Funding Acknowledgement Type of funding source: None

P3813The economic cost heterogeneity of patients with heart failure - a retrospective nationwide study

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
J S Bundgaard ◽  
U M Mogensen ◽  
S Christensen ◽  
U Ploug ◽  
R Roerth ◽  
...  
Keyword(s):  
Heart Failure ◽  
Economic Cost ◽  
Health Cost ◽  
Younger Age ◽  
Patients With Heart Failure ◽  
Male Sex ◽  
The Individual ◽  
The Cost ◽  
First Time ◽  
Time Diagnosis

Abstract Background Heart failure (HF) imposes a major economic burden, however the individual management for patients vary potentially leading to large cost heterogeneity. The aim of this study was to investigate the total direct health cost stratified across the spectrum of cost groups. Methods Using Danish nationwide registries from 2012 to 2015 we identified all patients >18 years with a first-time diagnosis of HF. Total health costs were investigated using two perspectives; at index and after 3 years (including index). We investigated the cost of patients in the highest cost group (highest 10%) vs. the lowest cost group (lowest 10%). A multivariable logistic regression was used to identify variables associated with being in the highest cost decile compared to the rest (90%). Results A total of 11,170 patients with HF were included and those in the highest cost decile (n=1,117, 10%) were younger (69 vs. 75 years), more males (43 vs. 34%), and more inpatients (83 vs. 70%) compared to the rest of the patients (n=10,053, 90%). Patients in the highest cost decile (10%) incurred a 30 times higher cost with a mean total health cost in index year of €86,607 compared to €2,893 for patients in lowest cost decile (10%) (Figure 1A). Results were similar for 3 years aggregated (€139,473 vs. €4,086), corresponding to a 34 times higher cost. At index year, variables associated with being in the highest cost decile included young age, male sex, inpatient admittance, renal disease, and several other comorbidities (Figure 1B). Conclusion Among patients with HF a large total direct health cost heterogeneity exists with younger age, inpatient admittance, male sex, and comorbidities being associated with a higher likelihood of belonging to the highest cost group. Acknowledgement/Funding Novartis

scholarly journals Myocarditis Incidence, Complications and Mortality in Sweden: A Retrospective Registry Study From 2000-2014

2021 ◽  
Author(s):  
Michael Fu ◽  
Silvana Kontogeorgos ◽  
Erik Thunström ◽  
Tatiana Zverkova Sandström ◽  
Christian Kroon ◽  
...  
Keyword(s):  
Total Population ◽  
Reference Population ◽  
Inflammatory Heart Disease ◽  
Hazard Ratios ◽  
Younger Men ◽  
National Patient ◽  
One Year ◽  
Complications And Mortality ◽  
First Time ◽  
Time Diagnosis

Abstract Objectives: Investigate trends in incidence and prognosis of myocarditis in Sweden during 2000-2014.Background: Myocarditis is an inflammatory heart disease, with scarce data concerning incidence and prognosis.Methods: Linking Swedish National Patient and Cause of Death Register, we identified individuals ≥16 years with first-time diagnosis of myocarditis during 2000-2014. Reference population, matched for age and birth year (n=16 622) was selected from the Swedish Total Population Register. Results: Among the 8 679 cases, (75% men, 64% <50 years), incidence rate/100 000 inhabitants rose from 6.3 to 8.6, mostly in men and those <50 years. Incident heart failure/dilated cardiomyopathy occurred in 6.2% within 1 year after index hospitalization and in 10.2% during 2000-2014, predominantly in those ≥50 years (12.1% within 1 year, 20.8% during 2000-2014). In all, 8.1% died within 1 year, 0.9% (<50 years) and 20.8% (≥50 years). Hazard ratios (adjusted for age, sex) for 1-year mortality comparing cases and controls were 4.00 (95% confidence interval 1.37-11.70), 4.48 (2.57-7.82), 4.57 (3.31-6.31) and 3.93 (3.39-4.57) for individuals aged <30, 30-<50, 50-<70, and ≥70 years, respectively. Conclusion: The incidence of myocarditis during 2000-2014 increased, predominantly in younger men. One-year mortality in the young was low, but fourfold higher compared with reference population.

Neotropical Meliponini: the genus Celetrigona Moure (Hymenoptera: Apidae, Apinae)

Zootaxa ◽  
2009 ◽  
Vol 2155 (1) ◽  
pp. 37-54 ◽  
Author(s):  
JOÃO M. F. CAMARGO ◽  
SILVIA R. M. PEDRO
Keyword(s):  
New Species ◽  
Identification Key ◽  
Three New Species ◽  
First Time ◽  
Time Diagnosis

Three new species of Celetrigona are described: C. euclydiana sp. nov., from Acre, Brazil, C. hirsuticornis sp. nov., from Rondônia, Brazil and C. manauara sp. nov., from the northern Amazon. Additional geographic records are provided for C. longicornis (Friese, 1903), the only previously known species; its nest and the male are described and illustrated for the first time. Diagnosis and an identification key for species are provided, which are distinguished by the pattern of pilosity on the antenna.

scholarly journals Incidence of myocardial infarction, heart failure, and cardiovascular mortality in patients with peripheral artery disease: nationwide trends between 1997 and 2016

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
S Kamil ◽  
T S G Sehested ◽  
K Houlind ◽  
J F Lassen ◽  
G Gislason ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Peripheral Artery Disease ◽  
Cumulative Incidence ◽  
Incidence Rates ◽  
Peripheral Artery ◽  
The Past ◽  
Artery Disease ◽  
First Time ◽  
Time Diagnosis

Abstract Background Over the past decades there has been a shift in cardiovascular (CV) risk factors with improved outcomes. Updated trends in incidence of myocardial infarction (MI) and heart failure (HF) in peripheral artery disease (PAD) are warranted. Purpose We aimed to investigate trends in the incidence of MI, HF, and CV mortality in PAD patients during the past two decades. Methods Nationwide registers were used to identify all patients aged ≥18 years, with first-time diagnosis of PAD between 1997 and 2016. Age-standardized incidence rates per 1,000 person-years (IR) were calculated to estimate trends of MI, HF, and CV mortality. Furthermore, risk of MI, HF, and CV mortality was estimated by 1-year cumulative-incidence with death as competing risk. Results A total of 136,746 patients with first-time diagnosis of PAD were included. Mean age was 70.01 [IQR 61–77 years], and 53.05% of the identified patients were male. The 1-year cumulative-incidence of MI in patients with PAD were 1.88% for year 1997–2000, 2.12% for year 2001–2005, 1.59% for year 2006–2010, and 1.32% for year 2011–2016, respectively. The 1-year cumulative-incidence of HF in patients with PAD were 1.71%, 1.48%, 1.25%, and 1.11% for the 1997–2000, 2001–2005, 2006–2010, and 2011–2016 year-groups, respectively. Furthermore the 1-year cumulative-incidence of CV mortality in patients with PAD were 12.0%, 9.41%, 8.75%, and 7.80% for the 1997–2000, 2001–2005, 2006–2010, and 2011–2016 year-groups, respectively. Likewise, the age-standardized incidence rates pr. 1,000 person-years showed increasing trends of MI up until 2002 with an estimated annual percent change (APC) of +0.6 (95% CI 3.3–16.1, p-value 0.2). After year 2002 the IR decreased significantly with an estimated APC of −5.0 (95% CI 3.7–6.3, p&lt;0.0001). The age-standardized IR for HF decreased with an estimated APC of −3.3 (95% CI 2.0–4.6, p&lt;0.0001), and similarly for CV death decreased by −3.5 (95% CI 3.0–4.0, p&lt;0.0001). Conclusion The incidence of MI and HF in patients with PAD has significantly decreased over time together with a subsequent decline in CV mortality. This may suggest that the improvements in preventive strategies aimed at reducing CV risk are effective and contributes to lower incidence of MI and HF and thereby improved mortality rates in the past two decades. FUNDunding Acknowledgement Type of funding sources: None.

Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature

2015 ◽  
Vol 173 (2) ◽  
pp. 269-273 ◽  
Author(s):  
O M Dekkers ◽  
V Ehrenstein ◽  
M Bengtsen ◽  
D Kormendine Farkas ◽  
A M Pereira ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Meta Analysis ◽  
Population Based ◽  
Incidence Rates ◽  
Increased Risk ◽  
Combining Data ◽  
First Time ◽  
Time Diagnosis

ObjectiveTo enhance the precision of the risk estimate for breast cancer in hyperprolactinemia patients by collecting more data and pooling our results with available data from former studies in a meta-analysis.DesignPopulation-based cohort study and meta-analysis of the literature.MethodsUsing nationwide registries, we identified all patients with a first-time diagnosis of hyperprolactinemia during 1994–2012 including those with a new breast cancer diagnoses after the start of follow-up. We calculated standardised incidence ratios (SIRs) as a measure of relative risk (RR) using national cancer incidence rates. We performed a meta-analysis, combining data from our study with data in the existing literature.ResultsWe identified 2457 patients with hyperprolactinemia and 20 breast cancer cases during 19 411 person-years of follow-up, yielding a SIR of 0.99 (95% CI 0.60–1.52). Data from two additional cohort studies were retrieved and analyzed. When the three risk estimates were pooled, the combined RR was 1.04 (95% CI 0.75–1.43).ConclusionsWe found no increased risk of breast cancer among patients with hyperprolactinemia.

scholarly journals First record of the genus Oedoparena Curran, 1934 (Diptera: Dryomyzidae) from Russia

2021 ◽  
Vol 442 ◽  
pp. 13-17
Author(s):  
A.L. Ozerov ◽  
◽  
M.G. Krivosheina ◽  
Keyword(s):  
First Record ◽  
Kuril Islands ◽  
Shikotan Island ◽  
First Time ◽  
Time Diagnosis

The genus Oedoparena Curran, 1934 (Diptera: Dryomyzidae) with species O. minor Suwa, 1981 is recorded from Russia (Kuril Islands: Shikotan Island) for the first time. Diagnosis of the genus and description of the species are given.

First-time Diagnosis of Severe Depression

2005 ◽  
Vol 25 (4) ◽  
pp. 399-400 ◽  
Author(s):  
Alexandra B. Whitworth ◽  
Wolfgang Aichhorn
Keyword(s):  
Severe Depression ◽  
First Time ◽  
Time Diagnosis

Factors associated with hematuric struvite crystalluria in cats

2018 ◽  
Vol 21 (10) ◽  
pp. 922-930
Author(s):  
Chika C Okafor ◽  
David L Pearl ◽  
Shauna L Blois ◽  
Sandra L Lefebvre ◽  
Mingyin Yang ◽  
...  
Keyword(s):  
Clinical Importance ◽  
Urine Ph ◽  
Factors Associated ◽  
The Usa ◽  
History Of ◽  
Dry Diet ◽  
First Time ◽  
Time Diagnosis ◽  
General Care

Objectives The aim of the study was to identify any dietary, signalment, geographic and clinical factors associated with hematuric struvite crystalluria (HSC) in a population of cats that visit general care veterinary hospitals in the USA. Methods In total, 4032 cats that had a first-time diagnosis of HSC and 8064 control cats with no history of hematuria or crystalluria were identified from medical records of all cats examined between 2007 and 2011 at 790 US veterinary hospitals. Extracted variables included age, sex, neuter status, breed, diet, urinalysis results and history of cystitis. Potential associations between these variables and HSC were estimated. Results Controlling for other factors, young cats fed a dry diet had an increased likelihood of HSC relative to young cats fed a non-dry diet. However, as age increased, the likelihood of HSC declined for cats fed a dry diet and increased for cats fed a non-dry diet. Moreover, the odds of HSC were significantly greater when cats were unneutered (vs neutered; odds ratio [OR] 45.52) or had a thin (vs heavy) body condition (OR 23.81), diagnosis of cystitis (OR 2.84), urine protein concentration >30 mg/dl (OR 4.72), alkaline (vs neutral) urine pH (OR 3.34), pyuria (OR 23.67) or bacteriuria (OR 2.24). Conclusions and relevance The present study provides estimates of the strengths of association between HSC and certain signalment and clinical characteristics of cats. This information could help clinicians to perform a more directed screening for struvite crystalluria in certain cat populations. Follow-up studies that build on the findings of this study could explore the clinical importance of HSC in cats.

Sign in / Sign up

Export Citation Format

Share Document